Gå ubegrenset med Magzter GOLD
Få ubegrenset tilgang til over 9000 magasiner, aviser og premiumhistorier for bare
Prøve GULL - Gratis
PLI boost: Cancer drugs to cost less
Mint Mumbai
|March 05, 2025
Cancer patients facing prohibitive treatment costs in India can hope for relief.
The nation's top drugmakers have started manufacturing key medicines for such diseases in the country.
India's largest drugmaker Sun Pharmaceutical Industries Ltd and its peers Cipla Ltd, Glenmark Pharmaceuticals Ltd, Cadila Healthcare Ltd and Biocon Ltd are making cancer drugs under the production-linked incentive (PLI) scheme, according to information shared by the department of pharmaceuticals with Mint. They are among the 55 companies selected for incentives to produce 175 high-value medicines in India.
At present, most cancer drugs are imported, making them prohibitively expensive. That's when India's cancer burden is expected to rise from 26.7 million life years or DALYS-the sum of healthy life lost to a disease-in 2021 to 29.8 million in 2025, according to data from the Indian Council of Medical Research (ICMR).
Denne historien er fra March 05, 2025-utgaven av Mint Mumbai.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA Mint Mumbai
Mint Mumbai
Sun Pharma rejig sets stage for Shanghvi's succession
Dilip Shanghvi is now executive chairman, son Aalok to oversee critical US business
2 mins
September 20, 2025
Mint Mumbai
Apple on track for record quarter on iPhone 17 sales
Sales volume, value expected to rise; top models sold out at three Apple Stores
3 mins
September 20, 2025
Mint Mumbai
Vodafone Idea investors cheer on hope of solution to new AGR case
Vodafone Idea Ltd investors celebrated after the Centre sought time to resolve the latest dispute over its statutory dues, citing consumer interest and its own stakeholding in the beleaguered telco.
2 mins
September 20, 2025
Mint Mumbai
The many shades of tea
My 13-year-old has taken to sharing Reels on the absurdities of language and how it can confuse one terribly if you're a new learner trying to grasp the rules.
2 mins
September 20, 2025
Mint Mumbai
Thyssenkrupp bid a litmus test for Jindal scion
Jindal Steel International’s pursuit of Thyssenkrupp Steel Europe marks a crucial moment for the group, and for its next-generation leader-in-waiting, Venkatesh Jindal.
3 mins
September 20, 2025
Mint Mumbai
Nvidia’s Huang walks an AI tightrope between US, China
Nvidia CEO Jensen Huang is trying to keep both the U.S. and China happy. It is proving to be a tricky high-wire act.
4 mins
September 20, 2025
Mint Mumbai
A tough test stands in the way of India’s ₹10 lakh-plus funds
Mutual funds are rolling out specialized investment funds (SIFs) with a minimum ₹10 lakh ticket size, but the product faces a distribution hurdle.
3 mins
September 20, 2025
Mint Mumbai
Life's little tragedies, comedies and ironies
Hindi journalist Anil Yadav's short fiction in translation throws light on corruption, hypocrisy and everyday absurdities in Varanasi, and beyond
4 mins
September 20, 2025
Mint Mumbai
Food safety watchdog sniffs for spice adulteration
India's food safety regulator has ordered an enforcement blitz on spice manufacturers across the country, in a move to combat adulteration and safeguard public health.
1 mins
September 20, 2025
Mint Mumbai
Flex those flaxseeds for an extra dose of nutrition
This seed ties together fabric, food and fine art.
4 mins
September 20, 2025
Listen
Translate
Change font size